India to Philippines: Amikacin Export Trade Route

To import Amikacin formulations into the Philippines, the following approvals and registrations are necessary:

1. License to Operate (LTO): Importers must obtain a valid LTO from the Philippine FDA, authorizing them to engage in the importation of pharmaceutical products.

2. Certificate of Product Registration (CPR): Each Amikacin formulation intended for importation must have a CPR issued by the FDA, confirming its safety, efficacy, and quality.

3. Dossier Submission: Applicants are required to submit a Common Technical Document (CTD) or electronic CTD (eCTD) dossier, encompassing comprehensive data on the product's quality, safety, and efficacy.

4. Approval Timelines: While specific timelines may vary, the FDA endeavors to process applications efficiently. Applicants should anticipate a review period and plan accordingly.

5. Product Registration Fees: Fees are applicable for both the LTO and CPR applications. The exact amounts are specified in the FDA's current fee schedule.

6. GMP Inspection Requirements: The FDA mandates Good Manufacturing Practice (GMP) compliance for foreign manufacturing facilities. Indian manufacturers exporting to the Philippines must provide evidence of GMP certification, which may involve inspections by the FDA or recognition of inspections conducted by other regulatory authorities.

Indian exporters of Amikacin formulations must adhere to the following GMP standards to supply the Philippine market:

1. GMP Certification: Manufacturing facilities must possess a valid GMP certificate recognized by the Philippine FDA. This certification ensures that the production processes meet international quality standards.

2. Approved Facilities: The FDA maintains a list of foreign manufacturers with valid GMP certificates. Indian facilities intending to export to the Philippines should verify their inclusion on this list.

3. Recent Inspections and Regulatory Actions: The FDA conducts periodic inspections of foreign manufacturing sites to ensure ongoing compliance with GMP standards. Any non-compliance identified during these inspections can result in regulatory actions, including suspension or revocation of GMP certification. Indian exporters should stay informed about inspection schedules and outcomes to maintain their certification status.

Several regulatory changes have occurred in the past 18 months affecting pharmaceutical imports into the Philippines:

1. Administrative Order No. 2024-0013: Effective December 11, 2024, this order outlines the general rules and regulations for the registration of pharmaceutical products and active pharmaceutical ingredients intended for human use. It aims to streamline the registration process and align with international standards.

2. Administrative Order No. 2024-0012: Implemented on October 24, 2024, this order prescribes the rules and regulations on the registration of pharmaceutical products and active pharmaceutical ingredients intended solely for export. While primarily focused on export, it underscores the FDA's commitment to regulatory harmonization and may influence import regulations indirectly.

These developments reflect the Philippine FDA's ongoing efforts to enhance regulatory processes, ensuring the safety, efficacy, and quality of pharmaceutical products within the country.

Amikacin, an aminoglycoside antibiotic, is primarily used in the treatment of severe bacterial infections, including those caused by multidrug-resistant strains. The demand for Amikacin formulations in the Philippines is influenced by factors such as the prevalence of hospital-acquired infections, the burden of multidrug-resistant tuberculosis, and the overall healthcare expenditure. In 2024, the Philippines' healthcare spending was estimated at approximately $20 billion, reflecting a steady increase in investment towards improving healthcare infrastructure and access to essential medicines. While specific data on the domestic production of Amikacin formulations is limited, the country relies on imports to meet a significant portion of its demand. In 2025, the Philippines imported Amikacin formulations valued at $0.5 million from India alone, indicating a substantial dependence on foreign suppliers to fulfill its requirements.

The Philippines imposes an MFN import duty rate of 2.5% on pharmaceutical products classified under HS code 30049099, which includes Amikacin formulations. In addition to the import duty, imported pharmaceuticals are subject to a Value-Added Tax (VAT) of 12%. The Philippines and India are both members of the Association of Southeast Asian Nations (ASEAN) and the South Asian Association for Regional Cooperation (SAARC), respectively. However, there is no specific Free Trade Agreement (FTA) between the two countries that provides preferential tariff rates for pharmaceutical imports. As of March 2026, there are no anti-dumping duties imposed on Amikacin formulations imported into the Philippines from India.

India is a key supplier of Amikacin formulations to the Philippines, accounting for $0.5 million in imports in 2025, which represents 2.5% of India's total Amikacin formulation exports valued at $21.1 million. Other major countries supplying Amikacin formulations to the Philippines include China and various European Union (EU) member states. While specific data on the market shares of these countries is not readily available, India's competitive pricing and established pharmaceutical manufacturing capabilities position it as a significant player in the Philippine market. Indian pharmaceutical manufacturers are known for offering cost-effective formulations, which often makes their products more affordable compared to those from EU manufacturers. This pricing advantage, coupled with the quality of Indian pharmaceuticals, contributes to India's strong presence in the Philippine Amikacin market.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the world's supply by volume. This extensive manufacturing base includes a significant capacity for producing finished dosage forms containing Amikacin, such as injections. The country's cost-effective production is attributed to economies of scale, a well-established supply chain, and a skilled workforce. As of 2025, India hosts over 400 WHO-GMP certified facilities and more than 200 US FDA-approved plants, ensuring compliance with stringent international quality standards.

When comparing Amikacin formulation exports, India offers a competitive advantage over China and the European Union (EU). Indian manufacturers provide cost-effective finished dosage forms without compromising quality, adhering to international regulatory standards. In contrast, Chinese generic formulations have faced scrutiny over manufacturing and quality concerns, leading to recalls and regulatory actions. The EU, while known for high-quality branded generics, typically presents higher price points. In the Philippines, Indian Amikacin formulations are well-accepted, with a strong track record of regulatory compliance and supply reliability.

The India-Philippines supply chain for Amikacin formulations is robust, supported by India's substantial manufacturing capacity and advanced packaging and cold chain logistics. Indian manufacturers have demonstrated consistent regulatory compliance, with facilities regularly inspected and approved by international bodies such as the US FDA and WHO. Recent expansions, including new facilities and capacity enhancements, indicate a commitment to meeting growing global demand. No significant supply disruptions have been reported in recent years, underscoring the reliability of Indian suppliers.

For Philippine buyers sourcing Amikacin formulations from India, consider the following strategies:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a steady supply chain.

• Minimum Order Quantities (MOQs): Be aware that MOQs may vary among suppliers; negotiate terms that align with your demand forecasts and storage capabilities.

• Payment Terms: Standard payment terms in India-Philippines pharmaceutical trade often include letters of credit or advance payments; establish clear agreements to maintain smooth transactions.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and compliance checks, to ensure suppliers meet international quality standards and regulatory requirements.

• Regulatory Compliance: Verify that the selected suppliers have the necessary approvals from Philippine regulatory authorities to facilitate seamless importation and distribution.

By meticulously following these guidelines, Philippine companies can establish robust supplier relationships with Indian manufacturers, ensuring the consistent quality and regulatory compliance of Amikacin formulations imported into the Philippines.